Relapsed acute lymphoblastic leukaemia (ALL) is a leading cause of death due to disease in young people, but the biological determinants of treatment failure remain poorly understood. Recent genome-wide profiling of structural DNA alterations in ALL have identified multiple submicroscopic somatic mutations targeting key cellular pathways 1, 2 , and have demonstrated substantial evolution in genetic alterations from diagnosis to relapse 3 . However, DNA sequence mutations in ALL have not been analysed in detail. To identify novel mutations in relapsed ALL, we resequenced 300 genes in matched diagnosis and relapse samples from 23 patients with ALL. This identified 52 somatic non-synonymous mutations in 32 genes, many of which were novel, including the transcriptional coactivators CREBBP and NCOR1, the transcription factors ERG, SPI1, TCF4 and TCF7L2, components of the Ras signalling pathway, histone genes, genes involved in histone modification (CREBBP and CTCF), and genes previously shown 1,2 to be targets of recurring DNA copy number alteration in ALL. Analysis of an extended cohort of 71 diagnosis-relapse cases and 270 acute leukaemia cases that did not relapse found that 18.3% of relapse cases had sequence or deletion mutations of CREBBP, which encodes the transcriptional coactivator and histone acetyltransferase CREBbinding protein (CREBBP, also known as CBP) 4 . The mutations were either present at diagnosis or acquired at relapse, and resulted in truncated alleles or deleterious substitutions in conserved residues of the histone acetyltransferase domain. Functionally, the mutations impaired histone acetylation and transcriptional regulation of CREBBP targets, including glucocorticoid responsive genes. Several mutations acquired at relapse were detected in subclones at diagnosis, suggesting that the mutations may confer resistance to therapy. These results extend the landscape of genetic alterations in leukaemia, and identify mutations targeting transcriptional and epigenetic regulation as a mechanism of resistance in ALL.
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Acute lymphoblastic leukaemia (ALL) is the commonest childhood malignancy 5 , and is a leading cause of cancer-related death in young people. Several structural chromosomal alterations in ALL, including rearrangement of MLL and the Philadelphia chromosome 6 are associated with a high risk of treatment failure and relapse. However, many ALL cases that fail therapy lack these alterations, and the biological basis of treatment failure in these cases is poorly understood. Genomewide profiling of ALL has identified multiple recurring submicroscopic genetic alterations targeting lymphoid development, cell cycle regulation, tumour suppression and apoptosis 1, 2 , and has identified genetic alterations that predict a high risk of relapse, including deletion of IKZF1 (encoding the transcription factor IKAROS) 7, 8 . Moreover, profiling of structural DNA alterations in matched diagnosis and relapse samples has demonstrated that in the majority of cases there are substantial differences in the complement of genetic lesions between diagnosis and relapse, although the predominant clones at both stages of disease share a common ancestral origin 3, 9 . The predominant clones at relapse are commonly present at low levels at diagnosis, suggesting that specific genetic alterations may confer resistance to therapy. Frequently acquired lesions at relapse include deletions of CDKN2A/ B, ETV6 and IKZF1 3, 9 . However, a detailed analysis of sequence variation in ALL has not been performed.
To identify novel sequence mutations in relapsed ALL, we resequenced 300 genes in matched diagnosis-relapse samples from 23 children with B-cell progenitor ALL. Cases studied included B-cell progenitor ALL with high hyperdiploidy (N 5 3), TCF3-PBX1 (N 5 1), ETV6-RUNX1 (N 5 3), rearrangement of MLL (N 5 3), BCR-ABL1 (N 5 3), and low hyperdiploid, pseudodiploid, or miscellaneous karyotypes (N 5 10) (Supplementary Table 1) . We sequenced genes known to be mutated in leukaemia and cancer, and those that encode pathway components targeted by recurring copy number alteration in ALL, tumour suppressors, cell cycle regulators, tyrosine kinases, and genes encoding DNA repair proteins (Supplementary Table 2 ). We identified 52 somatic (non-inherited) protein coding variants in 32 genes in 20 cases (mean 2.5 variants per case, range 0-5) (Supplementary Table 3 ). Somatic mutations were identified in genes previously known to be mutated in haematopoietic malignancies and ALL, including the ETS-family transcription factor gene ETV6 (N 5 1); the Janus kinase gene JAK1 (N 5 1); the Ras pathway genes NRAS (N 5 5; Supplementary Table  4 and Supplementary Fig. 1 ), KRAS (N 5 2), NF1 (N 5 3) and PTPN11 (N 5 2); the B-lymphoid transcription factor gene PAX5 (N 5 2); the U3 ubiquitin ligase gene FBXW7 (N 5 1) ; the histone methyltransferase gene EZH2 (N 5 1); and the tumour suppressor gene TP53 (N 5 2). In addition, we observed patterns of evolution of sequence variations between diagnosis and relapse that recapitulated those observed for DNA copy number alterations in ALL 3 (Table 1,  Supplementary Results and Supplementary Table 4) .
A novel finding was somatic coding mutations in CREBBP (or CBP, encoding CREB-binding protein) in four of 23 cases sequenced (Supplementary Table 5 ). CREBBP was selected for sequencing by identifying recurring focal deletions involving the gene. CREBBP and its paralogue, EP300 (p300) are transcriptional coactivators with multiple functions in development and haematopoiesis 4, 10, 11 . Both are molecular scaffolds that interact with a diverse range of transcription factors, regulate transcription by acetylation of histone and nonhistone targets, and may regulate protein turnover by E4 polyubiquitin ligase activity. CREBBP and EP300 are known targets of translocations in acute leukaemia (for example, MLL-EP300, MLL-CREBBP, MOZ-CREBBP and MOZ-EP300) 12 . Inherited CREBBP mutations and deletions result in the Rubinstein-Taybi syndrome, a developmental disorder characterized by dysmorphology, intellectual impairment, and an increased susceptibility to solid tumours 13, 14 . Homozygous deletion of Crebbp or Ep300 is lethal in mice owing to developmental abnormalities, and Crebbp 1/2 mice show defects in B lymphoid development, and an increased incidence of haematopoietic tumours 15 . Although CREBBP and EP300 sequence mutations have been reported in solid tumours 16, 17 and rare EP300 mutations have been detected in an ALL cell line and myelodysplasia 18 , there are no prior reports of CREBBP sequence mutations in haematologic malignancies.
To define the frequency of CREBBP and EP300 mutations in acute leukaemia, we sequenced these genes in an additional 318 cases of paediatric leukaemia. These additional cases included matched diagnosis and relapse samples from 48 children with ALL, and diagnosis samples from children with ALL (N 5 170) and acute myeloid leukaemia (AML, N 5 100) 19 that did not relapse. Single nucleotide polymorphism (SNP) microarray DNA copy number alteration and loss-of-heterozygosity data were available for all cases sequenced 1, 20, 21 . We also examined DNA copy number alterations in a further 107 ALL cases that were not sequenced 1, 3, 20 . In addition, CREBBP was sequenced in 58 ALL and AML cell lines. Remarkably, 13 of 71 (18.3%) of relapsed ALL cases harboured either tumour-acquired (non-inherited) sequence alterations (N 5 13) or focal deletions (N 5 2) of CREBBP (Supplementary Table 5 and Supplementary Fig. 2 ). In contrast, CREBBP alterations in cases of childhood acute leukaemia that did not relapse were rare, with only one additional CREBBP mutation identified in 200 AML and ALL cases sequenced (ALL patient Hyperdiploid-#22, C1408Y, Supplementary Table 5 ). Furthermore, three of 307 ALL cases with SNP array data had focal CREBBP deletions at diagnosis (Supplementary Table 5 and Supplementary Fig. 2 ). CREBBP alterations were not observed in AML. . CREBBP R1446 (equivalent to EP300 R1410) contacts phosphates of the CoA moiety of the inhibitor (salt bridges are shown as dashed lines), and the R1446H mutation is predicted to disrupt substrate binding. Q1500P (EP300 Q1464) is predicted to disrupt the a4 helix, which stabilizes the substrate binding loop L1 between the b5 strand and the a4 helix. C1408H (EP300 C1372) is predicted to disrupt the hydrophobic core that involves both the amino and carboxy termini of the HAT domain. R1563 cannot be shown because this residue lies in a proteolytically sensitive autoacetylation loop that was deleted in order to generate the crystal structure 22 . c, Sequence traces (labelled with nucleotide, and corresponding amino acid residues R, C, L and R/H) showing duplication of the R1446H mutation at relapse for patient H50-#53. This mutation was heterozygous at diagnosis and absent in the matched normal sample. There is copy-neutral loss of heterozygosity (LOH) of chromosome 16p at relapse but not at diagnosis. D v N is the LOH analysis of diagnosis sample compared to matched normal sample; R v N is the relapse compared to matched normal sample. Cent, centromere; 16ptel, chromosome 16p telomere; 16qtel, chromosome 16q telomere. d, Sequence traces (labelled with nucleotide, and corresponding amino acid residues S, K, P and Q). In patient Other-#42, CREBBP mutations are present in subclones at diagnosis, and emerge in the predominant clone at relapse. The S1761* mutation is heterozygous in the relapse sample, absent in the matched normal sample, and appears as a minor peak in the diagnosis sample. Presence of this mutation in a subpopulation of cells at diagnosis was confirmed by PCR, cloning and bidirectional sequencing of multiple colonies of the diagnosis sample (data not shown).
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Only one EP300 mutation was detected in the 71 cases that relapsed, a missense mutation (P925L) acquired at relapse. The identified CREBBP mutations resulted in amino acid substitutions, most commonly in the histone acetyltransferase (HAT) domain, or truncating frameshift or nonsense changes (Fig. 1a) . The HAT mutations involved highly conserved residues (Supplementary Fig. 3 ). Modelling of the predicted effects of the CREBBP HAT mutations using the crystal structure of the highly homologous EP300 HAT domain 22 demonstrated that the mutations are likely to disrupt the structure of the domain or its interaction with substrates (Fig. 1b) .
Notably, CREBBP mutations present at diagnosis were retained or duplicated at relapse. Three cases had biallelic CREBBP mutations, either compound heterozygosity for different mutations, or homozygosity for a single mutation (Q1500P). Q1500P, but none of the other mutations identified in ALL, is also observed in Rubinstein-Taybi syndrome 13 . Homozygosity for this mutation was accompanied by DNA copy-neutral loss-of-heterozygosity (acquired uniparental disomy) of chromosome 16p in both diagnosis and relapse samples, but not the germline sample in this case. This was identified on analysis of SNP microarray genotype data for this patient, indicating that one copy of 16p containing the wild-type CREBBP allele had been deleted, while the remaining copy of 16p harbouring the Q1500P allele had been duplicated. One case (patient Hyperdiploid-#53) had a heterozygous HAT domain mutation (R1446H) at diagnosis that was homozygous at relapse with accompanying copy-neutral loss-of-heterozygosity of 16p, again indicating duplication of the mutated allele in the predominant relapse clone (Fig. 1c) . Furthermore, three mutations detected at relapse (T1070fs, S1761* and I2101M) were detected at low levels in the diagnosis sample (Fig. 1d) .
Together, the high frequency of CREBBP mutations in relapsed ALL, the persistence, reduplication or emergence of mutations from diagnosis to relapse, and the location of the mutations in key CREBBP functional domains suggest that these alterations impair CREBBP function and influence treatment responsiveness. CREBBP is expressed in Relative expression normalized to Pgk1
Relative expression normalized to Pgk1 ;Ep300 Dflox/Dflox (dKO) MEFs and dKO MEFs transduced with retrovirus expressing wild type (1Crebbp) and mutant haemagglutinin (HA)-tagged Crebbp. Four independent experiments with separate controls were performed, one of which is shown. S1887* truncates the protein before the C-terminal HA-tag, but is predicted to retain the HAT domain. b, Quantification of H3K18Ac mean signal intensity per nucleus relative to the HA-tagged Crebbp retrovirus mean signal intensity. Values are mean 6 s.e.m.; 40-61 nuclei quantified per retrovirus. Only nuclei that have an HA-tag (Crebbp-HA) signal greater than 2.5-fold above background were included. Data are expressed as the ratio of the mean H3K18Ac signal intensity for each nucleus to the mean HA signal intensity for the same nuclei. The P value shown is from a Tukey post-test of one-way analysis of variance (ANOVA); mean 6 standard error of the mean. c, Quantitative reverse transcription (RT)-PCR gene expression data from dKO MEFs transduced with wild-type or mutant CBP, and treated with ethanol (vehicle) or with 10 mM forskolin 1 100 mM IBMX for 90 min. W1502A/Y1503S (WY/AS) is a previously described mutation that inactivates HAT enzymatic activity 30 . Gene expression was normalized to expression of Pgk1. N 5 3-7. Supplementary Fig. 4) , and the mutant CREBBP alleles are expressed in ALL cell lines harbouring mutations (Supplementary Table 6 and Supplementary Fig. 5 ).
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We investigated the functional effect of the mutations in mice. We examinedthehistoneacetylationandtranscriptionalactivitiesofwild-type and mutant Crebbp alleles expressed in Crebbp Dflox/Dflox
;Ep300
Dflox/Dflox (CBP/p300 Cre-deleted double knockout, or dKO) primary murine embryonic fibroblasts (MEFs) [23] [24] [25] ( Fig. 2 and Supplementary Figs  6-10) . The CREBBP HAT mutations resulted in diminished acetylation of histone H3 lysine 18 (H3K18), a known acetylation substrate of CREBBP 25 ( Fig. 2a and b) . Notably, the acetylation was attenuated but not blocked, and differed between HAT mutants (Fig. 2a and b) . The Rubinstein-Taybi syndrome Q1500P mutation resulted in only a modest reduction in acetylation despite being predicted to disrupt a key a helix in the HAT domain (Fig. 1a) . This suggests that HAT mutants have additional deleterious effects beyond impairing histone acetylation, that H3K18 is not the critical substrate, or that attenuated HAT activity is sufficient for the phenotype. To investigate these possibilities, we examined the effects of the CREBBP mutations on the expression of Crebbp target genes and cell proliferation in dKO MEFs transduced with retrovirus expressing wild-type and mutant Crebbp complementary DNAs (Fig. 2c and Supplementary Figs 6-10). We tested mutations in the HAT domain, as well as S1761*, S1887* and I2101M, which are predicted to affect the nuclear coactivator binding domain (Fig. 1a) . Interestingly, the HAT mutants result in reduced expression of cyclic-AMP-responsive CREB target genes ( Fig. 2c and Supplementary Figs 6-8) . Furthermore, many of the mutants tested also impaired cell proliferation ( Supplementary Fig.  11 ). Truncating mutations within the carboxy-terminal region of the HAT domain affected the expression of double-stranded RNA and glucocorticoid-receptor-responsive genes ( Supplementary Fig. 8j-k and Supplementary Figs 9-10) , consistent with the role of the nuclear coactivator binding domain in these pathways. The magnitude of reduced expression depended on the target gene, the specific mutation and the pathway, but the finding that CREBBP mutations result in impaired expression of glucocorticoid-receptor-responsive genes is particularly notable. The glucocorticoid dexamethasone is a mainstay of therapy for ALL, and poor responsiveness to steroid therapy is strongly associated with poor treatment outcome 26 . Accordingly, we examined responsiveness to dexamethasone and the class I/II HDAC inhibitor vorinostat in a panel of T-lineage ALL cell lines with wildtype or mutant CREBBP alleles. This demonstrated dexamethasone resistance in the majority of cell lines, but sensitivity to vorinostat at clinically useful concentrations (half-maximum inhibitory concentration IC 50 below 1 mM) in the majority of cell lines tested (Supplementary Table 7 and Supplementary Fig. 12 ). This suggests that multiple mechanisms are likely to influence glucocorticoid responsiveness, but that HDAC inhibitor therapy may be useful in steroidresistant ALL.
These findings show that detailed analysis of sequence alterations in relapsed ALL can identify novel genetic alterations that are likely to be involved in the pathogenesis of treatment failure. Approximately 10% of the genes sequenced harboured somatic sequence mutations with multiple mutations involving transcriptional regulators and coactivators, many of which are targeted by other structural genetic alterations in ALL, including deletions and translocations (for example, PAX5, ERG, ETV6, CREBBP and EP300). These results, together with those of Pasqualucci et al. identifying a high frequency of CREBBP and EP300 mutations in diffuse large B-cell and follicular lymphoma 27 , also identify CREBBP and EP300 as new targets of recurring mutation in a range of lymphoid malignancies. The observation that the CREBBP mutations impair regulation of glucocorticoid-responsive genes, and that the mutations are selected for at relapse, suggests that these alterations may influence response to therapy and the likelihood of relapse. These results are also of clinical relevance, because they suggest that therapeutic approaches directed at modulating protein acetylation 28 may be useful in high-risk ALL, particularly as HDAC inhibitors may induce apoptosis in glucocorticoid-resistant leukaemic cells 29 . Finally, these results indicate that comprehensive evaluation of sequence alterations and epigenetic modifications in relapsed ALL is likely to yield further biological insights and potential therapeutic approaches for this disease.
METHODS SUMMARY
Sequencing of 300 genes was performed by polymerase chain reaction (PCR) and capillary resequencing of whole genome amplified DNA extracted from leukaemic cells obtained at diagnosis and relapse from 23 B-cell progenitor ALL cases. CREBBP and EP300 mutation recurrence testing was performed in an additional 48 diagnosis-relapse B-cell and T-cell ALL samples, and CREBBP was also sequenced in 270 ALL and AML samples that did not relapse. All putative mutations were validated as somatic by sequencing of corresponding remission DNA samples, and by sequencing of unamplified tumour and matched normal DNA. All cases had DNA copy number alteration data from Affymetrix 500K or SNP 6.0 microarrays. In vitro functional assays of CREBBP mutants. H13K18 acetylation, gene expression and cell proliferation were assayed in Crebbp Dflox/Dflox ;Ep300
Dflox/Dflox dKO MEFs [23] [24] [25] transduced with retroviral supernatants expressing wild-type and mutant Crebbp alleles. Dexamethasone and vorinostat drug response assays and all methods are described in full in the online-only Methods.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Patients and samples. Seventy-one children with matched diagnosis and remission ALL samples were studied, including 61 cases previously studied by SNP microarray analysis 3 . All samples had at least 80% blasts by immunophenotypic and/or morphologic analysis, or were flow-sorted to at least 90% purity before DNA extraction. Sequencing of 300 genes was performed for 23 B-cell progenitor ALL cases. CREBBP and EP300 mutation recurrence testing was performed in an additional 48 diagnosis-relapse B-cell and T-cell ALL samples. Samples obtained at diagnosis from 270 children with AML and ALL who did not experience relapse were also sequenced for CREBBP variants. This cohort comprised AML cases with translocation ( CREBBP and EP300 variants not present in matched germline samples were validated by repeat PCR and sequencing of unamplified DNA. PCR primer sequences, PCR reaction conditions, thermal cycling parameters and sequence traces are available upon request. Expression of CREBBP variants was confirmed by reverse transcription using Superscript III (Life Technologies) and PCR using either Phusion HF DNA polymerase (New England Biolabs) or BD Advantage DNA polymerase (Clontech). To detect low levels of relapse-acquired mutations in diagnosis samples, (RT-)PCR products were cloned into pGEM-T-Easy (Promega) and at least 24 colonies were bidirectionally sequenced. Sequence analysis. Base calls and quality scores were determined using the program PHRED 34, 35 . Sequence variations including substitutions and insertion/ deletions (indel) were analysed using the SNPdetector 36 and the IndelDetector 37 software. A usable read was required to have at least one 30-base pair (bp) window in which 90% of the bases have a PHRED quality score of at least 30. Poor-quality reads were filtered before variation detection. The minimum thresholds of secondary-to-primary peak ratio for substitution and indel detection were set to be 20% and 10%, respectively. All sequence variations were annotated using a previously developed variation annotation pipeline 38 . Any variation that did not match a known polymorphism (defined as a dbSNP record that does not belong to the OMIM SNP nor COSMIC somatic variation database 33, 39 ) and resulted in a non-silent amino acid change was considered a putative mutation. Sequence variants were visualized using Consed 40 . Western blotting. Western blotting of CREBBP/Crebbp of either whole-cell lysates or nuclear extracts 41 of leukaemia cell lines and MEFs was performed using anti-HA and anti-CREBBP (A22, Santa Cruz Biotechnology) antibodies. Structural modelling of CREBBP and EP300 HAT domain mutations. The HAT domain amino acid sequences of CREBBP and EP300 are highly homologous. The mutations in the HAT domain in EP300, and the homologous EP300 mutations corresponding to the CREBBP HAT mutations, were visualized using the solved crystal structure of a semi-synthetic heterodimeric EP300 HAT domain in complex with a bi-substrate inhibitor, Lys-CoA 22 (http://dx.doi.org/10.2210/ pdb3biy/pdb) 42 . Visualization was performed using Pymol 43 .
In vitro analyses of the effects of CREBBP mutations on target gene expression, histone acetylation, and cell proliferation MEF isolation and culture were performed as previously described 25 . MEF treatments used were for 90 min with 10 mM forskolin 1 100 mM IBMX or ethanol vehicle, 4 h with 1 mM dexamethasone or ethanol, or 1 h treatment with 100 mg ml 21 Poly I:C or PBS followed by a wash, medium change and incubation for 3 h before harvesting of cells into TRIzol (Life Technologies). Generation of mouse Crebbp (CBP)-HA retroviral constructs and retroviral transduction were performed as previously described 25 . Residue position numbering in the CBP-HA constructs is based on the conserved residue in human CREBBP. For all retroviral experiments except proliferation assays, retroviral transductions were 70% or higher. Quantitative RT-PCR, western blot and immunofluorescence protocols were described previously 25 . H3K18Ac (ab1191) (Abcam), HA-11 monoclonal antibody against the HA epitope (Boehringer Mannheim), CREBBP (A-22) and EP300 (N-20) (Santa Cruz Biotechnology) were used for immunofluorescence. CBP/p300 antiserum (2574) used for immunofluorescence was generated against GST-p300 1-328, but detects both CBP and p300 similarly by immunofluorescence. For proliferation assays, Crebbp flox/flox ;Ep300 flox/flox ;YFP MEFs were infected with CBP retrovirus, then endogenous CBP and p300 were deleted with adenovirus-Cre after 2 days (day 1 being the day following overnight adenovirus-Cre treatment). Yellow fluorescent protein (YFP) expression was activated in deleted cells. Proliferation assays were commenced with one million YFP 1 MEFs on day 1 and were passaged every 2-3 days. The total number of YFP 1 cells on day 11 was calculated from the total cell number and from YFP 1 percentage as determined by flow cytometry. Gene expression profiling of MEFs. Total RNA was extracted from untransduced dKO MEFs and dKO MEFs transduced with wild-type and mutant Crebbp alleles treated with vehicle or 1 mM dexamethasone for 4 h. RNA was processed and hybridized to HT MG-430 PM gene expression arrays (Affymetrix) according to the manufacturer's instructions. Probe sets were selected for visualization and validation that meet the criteria of threefold induction by dexamethasone in all four dKO 1 Crebbp-HA 1 dexamethasone samples and which had a minimal level of expression that is above twice the background ($3.1) for the same four samples. Dexamethasone and vorinostat drug response assays. The activities of dexamethasone (APP Pharmaceuticals) and vorinostat (Selleck Chemicals) were evaluated against nine T-cell ALL cell lines (Jurkat, HPB-ALL, SUPT1, MKB1, REX, P12/Ichikawa, TALL-1, LOUCY and PEER) using an MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell viability assay. Cells were treated with the indicated drug concentration for 72 h. Data were analysed as the mean percentage of dimethyl sulphoxide (DMSO)-treated control cells at each concentration. IC 50 values were calculated from the dose-response curves using nonlinear regression analysis as implemented in the computer software program Prism version 5.0 (GraphPad Software). For each drug and cell line, three to four independent experiments were performed with six replicates at each concentration. RESEARCH LETTER
